Rigvir — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Rigvir Group is a private biotech company based in Riga, Latvia, developing oncolytic virotherapy based on its proprietary ECHO-7 virus (Rigvir). The company's primary strategy involves licensing its technology for commercial production and therapeutic use, while also exploring non-medical applications like cancer prevention supplements. While Rigvir was registered as a medicine in Latvia in 2004, the company's current commercial focus appears to be on industrial/scientific sales and regional licensing deals rather than broad pharmaceutical commercialization.

Oncology

Technology Platform

Proprietary, non-genetically modified oncolytic ECHO-7 virus (Rigvir) platform for selective targeting and lysis of cancer cells.

Opportunities

Opportunities include monetizing the existing asset through regional licensing deals in under-served markets and capitalizing on the growing global interest in oncolytic virotherapy for industrial research.

The wellness supplement segment offers a potential high-volume, lower-regulatory-barrier revenue stream.

Risk Factors

Major risks include lack of contemporary clinical validation by major regulatory bodies, reputational damage from marketing a cancer therapy as a food supplement, and technological obsolescence as next-generation engineered oncolytic viruses advance.

Competitive Landscape

Rigvir competes in the oncolytic virotherapy space against approved products like Amgen's Imlygic and numerous clinical-stage candidates from companies like Replimune and Oncorus. Its non-engineered, natural virus platform is a differentiation but may be perceived as less potent or tunable than modern genetically modified viruses.

More companies in Immunotherapy / Immuno-Oncology →More companies in Europe - Other →